Immunohistochemical characteristics of MMP-9 and TIMP-1 markers expression in the cerebral cortex in diabetes mellitus type 2

Authors

  • V. O. Shavrin Zaporizhzhia State Medical University, Ukraine,
  • Yu. M. Avramenko Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2020.4.208355

Keywords:

diabetes mellitus, angiogenesis, MMP-9, TIMP-1, MMP-9/TIMP-1

Abstract

 

Aim – to study the features of immunohistochemical expression of MMP-9, TIMP-1, MMP/TIMP ratio in the cerebral cortex in diabetes mellitus type 2.

Materials and methods. A pathomorphological and immunohistochemical study of the section material of brain tissue conducted in 3 groups of observations: group I – control without diabetes and cerebrovascular pathology, group II – deceased patients with dyscirculatory-ischemic encephalopathy (DIE), group III – deceased patients with diabetes mellitus type 2 (DM).

Results. Increased expression of MMP-9 in DIE group and in deceased patients with DM type 2 (MMP-9 in the control group – 0.434 (0.399; 0.792) %, in DIE group – 0.652 (0.398; 1.103) %, in DM type 2 group – 0.829 (0.636; 1.034) % has been found. A significant decrease in TIMP-1 expression was detected in DM type 2 (TIMP-1 – in the control group 0.449 (0.254; 0.601) %, in group of DIE – 0.444 (0.306; 0.688) %, in DM type 2 group – 0.278 (0.196; 0.554) %. A statistically significant increase in the MMP/TIMP ratio (Р ˂ 0.05) was observed in DM, the median was 2.732 (1.665; 4.643); this indicator was 1.386 (0.618; 2.29) in the control group and 1.528 (0.619; 3.056) (Р ˃ 0.05) in DIE group.

Conclusions. An increase in the level of MMP-9 expression and a decrease in the expression level of TIMP-1 in the cerebral cortex in diabetes mellitus type 2 promote increased blood-brain barrier permeability and is an important link in the pathogenesis of diabetic microangiopathy.

 

References

Rempe, R. G., Hartz, A. M. S., & Bauer, B. (2016). Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. Journal of Cerebral Blood Flow & Metabolism, 36(9), 1481-1507. https://doi.org/10.1177/0271678X16655551

Reinhard, S. M., Razak, K., & Ethell, I. M. (2015). A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Frontiers in cellular neuroscience, 9, Article 280. https://doi.org/10.3389/fncel.2015.00280

Wadood, S. A., Shawk, R., & Hashem, R. (2015). Variants of MMP-9 and TIMP-1 levels could be a predictor of an early development of cardiovascular diseases in type 2 Diabetes among Iraqi patients. Iraqi Journal of Science, 56(1C), 622-632.

de Senna, P. N., Xavier, L. L., Bagatini, P. B., Saur, L., Galland, F., Zanotto, C., Bernardi, C., Nardin, P., Gonçalves, C. A., & Achaval, M. (2015). Physical training improves non-spatial memory, locomotor skills and the blood brain barrier in diabetic rats. Brain research, 1618, 75-82. https://doi.org/10.1016/j.brainres.2015.05.026

Setyopranoto, I., Malueka, R. G., Panggabean, A. S., Widyadharma, I., Sadewa, A. H., Lamsudin, R., & Wibowo, S. (2018). Association between Increased Matrix Metalloproteinase-9 (MMP-9) Levels with Hyperglycaemia Incidence in Acute Ischemic Stroke Patients. Open access Macedonian journal of medical sciences, 6(11), 2067-2072. https://doi.org/10.3889/oamjms.2018.459

Zhang, J.-X., Zhang, Z.-Y., & Cheng, Y. (2017). Elevated MMP-1 and TIMP-1 are related with acute cerebral infarction patients with diabetes mellitus. International Journal of Clinical and Experimental Medicine, 10(12), 16555-16561.

Piccardi, B., Palumbo, V., Nesi, M., Nencini, P., Gori, A. M., Giusti, B., Pracucci, G., Tonelli, P., Innocenti, E., Sereni, A., Sticchi, E., Toni, D., Bovi, P., Guidotti, M., Tola, M. R., Consoli, D., Micieli, G., Tassi, R., Orlandi, G., Perini, F., … Inzitari, D. (2015). Unbalanced Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases Ratios Predict Hemorrhagic Transformation of Lesion in Ischemic Stroke Patients Treated with Thrombolysis: Results from the MAGIC Study. Frontiers in neurology, 6, Article 121. https://doi.org/10.3389/fneur.2015.00121

Moore, C. S., & Crocker, S. J. (2012). An alternate perspective on the roles of TIMPs and MMPs in pathology. The American Journal of Pathology, 180(1), 12-16. https://doi.org/10.1016/j.ajpath.2011.09.008

Turner, R. J., & Sharp, F. R. (2016). Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. Frontiers in Cellular Neuroscience, 10, Article 56. https://doi.org/10.3389/fncel.2016.00056

Watanabe, R., Maeda, T., Zhang, H., Berry, G. J., Zeisbrich, M., Brockett, R., Greenstein, A. E., Tian, L., Goronzy, J. J., & Weyand, C. M. (2018). MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis. Circulation Research, 123(6), 700-715. https://doi.org/10.1161/circresaha.118.313206

Peres, G. B., Jasiulionis, M. G., & Michelacci, Y. M. (2014). Matrix Metalloproteases in Streptozotocin Model of Diabetes Mellitus. In E. L. Gauther (Ed.), Streptozotocin: Uses, Mechanism of Action and Side Effects (pp. 81-98). Nova Science Publishers.

Zhang, Z., Wu, X., Cai, T., Gao, W., Zhou, X., Zhao, J., Yao, J., Shang, H., Dong, J., & Liao, L. (2015). Matrix Metalloproteinase 9 Gene Promoter (rs 3918242) Mutation Reduces the Risk of Diabetic Microvascular Complications. International Journal of Environmental Research and Public Health, 12(7), 8023-8033. https://doi.org/10.3390/ijerph120708023

Lorente, L., Martín, M. M., Ramos, L., Cáceres, J. J., Solé-Violán, J., Argueso, M., Jiménez, A., Borreguero-León, J. M., Orbe, J., Rodríguez, J. A., & Páramo, J. A. (2015). Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction. BMC Neurology, 15, Article 111.

https://doi.org/10.1186/s12883-015-0364-7

Kowluru, R. A. (2010). Role of Matrix Metalloproteinase-9 in the Development of Diabetic Retinopathy and Its Regulation by H-Ras. Investigative Opthalmology & Visual Science, 51(8), 4320-4326. https://doi.org/10.1167/iovs.09-4851

Omar, G., Sayed, G., Ghanem, A., Mohamed, N., & El-Kholy, M. (2018). Association of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels with diabetic foot ulcer in Egyptians with type 2 diabetes mellitus. Journal of Medicine in Scientific Research, 1(4), 266-270. https://doi.org/10.4103/jmisr.jmisr_80_18

Morishita, T., Uzui, H., Mitsuke, Y., Amaya, N., Kaseno, K., Ishida, K., Fukuoka, Y., Ikeda, H., Tama, N., Yamazaki, T., Lee, J.-D., & Tada, H. (2017). Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Failure, 4(3), 321-330. https://doi.org/10.1002/ehf2.12137

Nagy, B., Woth, G., Mérei, Á., Nagy, L., Lantos, J., Menyhei, G., Bogár, L., & Mühl, D. (2016). Perioperative time course of matrix metalloproteinase-9 (MMP-9), its tissue inhibitor TIMP-1 & S100B protein in carotid surgery. Indian Journal of Medical Research, 143(2), 220-226. https://doi.org/10.4103/0971-5916.180212

Ikemoto, S., Matsuura, R., Hamano, S.-I., Daida, A., Kubota, J., Hirata, Y., & Koichihara, R. (2018). Elevated Serum MMP-9 and MMP/TIMP-1 Ratio in Patients with Migrainous Infarction and Hemiplegic Migraine. Journal of Neurology and Neuroscience, 9(6), Article 278. https://doi.org/10.21767/2171-6625.1000278

How to Cite

1.
Shavrin VO, Avramenko YM. Immunohistochemical characteristics of MMP-9 and TIMP-1 markers expression in the cerebral cortex in diabetes mellitus type 2. Zaporozhye Medical Journal [Internet]. 2020Jul.22 [cited 2024Nov.2];22(4). Available from: http://zmj.zsmu.edu.ua/article/view/208355

Issue

Section

Original research